2023 World Conference on Lung Cancer (Posters)-EP12.03. Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy

EP12.03. Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

This abstract discusses a study conducted in a Canadian healthcare system to examine the adverse events and outcomes in patients with non-small cell lung cancer (NSCLC) who received targeted therapy after immunotherapy. The study aimed to gather data on the safety outcomes of prescribing this treatment sequence, as more patients are receiving both tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI) for their NSCLC.<br /><br />The researchers used the Glans-Look Lung Cancer Research program database to identify patients with NSCLC in Alberta who were treated for oncogenic driver mutations with a TKI immediately following ICI therapy. Adverse events (AE) were categorized using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0, with serious AE (SAE) being those of grade 3 or greater or requiring intervention, treatment break, or discontinuation.<br /><br />The results showed that out of the 26 patients evaluated, 69.2% were never smokers, 92.3% had a performance status of 0 or 1, 65.4% had an EGFR driver mutation, and 76.9% presented with metastatic adenocarcinoma at diagnosis. SAE on TKI therapy were observed in 38.5% of cases, with a higher likelihood of being reported in patients aged over 70 years. Increased hepatic enzymes were the most common SAE observed, occurring in 19.2% of patients. Pneumonitis and myopericarditis were reported in the overall cohort at an event rate of 3.8% with a median 40 days to presentation.<br /><br />The study concludes that completing molecular profiling before treatment decisions could help balance treatment efficacy and safety. The data obtained support the current standard of care for molecularly targeted therapy prior to ICI in patients with known actionable oncogenic driver mutations, such as EGFR or ALK.<br /><br />Overall, the study provides important insights into the adverse events and outcomes of patients with NSCLC receiving targeted therapy after immunotherapy, highlighting the need for careful consideration of treatment sequencing and patient characteristics.

Asset Subtitle

Michelle Dean

Meta Tag

Speaker Michelle Dean

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

Canadian healthcare system

non-small cell lung cancer

NSCLC

targeted therapy

immunotherapy

adverse events

tyrosine kinase inhibitors

immune checkpoint inhibitors

oncogenic driver mutations

Glans-Look Lung Cancer Research program database